
Metagenomi, Inc.
93
Recent news reports highlight Metagenomi's continued financial losses and progress advancing MGX-001 toward IND submission. Quarterly results show ongoing net losses and revenue shortfalls relative to expectations.
- Metagenomi reported a wider Q2 loss as MGX-001 advanced toward IND submission in August 2026 [N1].
- The company reported Q2 losses and revenue below expectations in August 2026 [N2].
- Metagenomi reported Q1 losses and missed revenue expectations in May 2026 [N5].
- The company reported Q4 losses and missed revenue expectations in March 2026 [N7].
Metagenomi, Inc. is a biotechnology company specializing in genome editing technologies. Founded in 2018, the company is in early development stages with all programs in research or lead optimization. It has not initiated clinical trials or generated product revenue. Metagenomi finances operations through equity, debt, collaborations, and IPO proceeds. The company is advancing its lead candidate MGX-001 toward IND submission. Financially, it has incurred substantial losses and maintains liquidity to fund near-term operations. The company faces significant risks related to funding, regulatory approvals, product development, and commercialization.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Metagenomi, Inc. is an early-stage biotechnology company focused on genome editing. The company has incurred significant losses since inception and has not generated revenue from product sales. It is advancing its MGX-001 candidate toward IND submission. As of September 30, 2026, Metagenomi had $36.1 million in cash and cash equivalents and a current ratio of 3.43, indicating liquidity to support near-term operations. The company faces risks typical of early-stage biotech firms, including the need for substantial additional funding, regulatory challenges, and operational risks transitioning to clinical and commercial stages.
Metagenomi's advancement of MGX-001 toward IND submission demonstrates progress in its pipeline. The company's proprietary genome editing platform could enable development of novel therapies addressing unmet medical needs. Strong liquidity ratios as of September 2026 provide runway to support ongoing research and development activities. Strategic collaborations and successful clinical development could enhance the company's value proposition.
Metagenomi has a limited operating history and has not yet initiated clinical trials. The company has incurred significant losses and may require substantial additional funding to continue operations. Risks include potential delays or failures in product development, regulatory hurdles, competition, intellectual property challenges, and operational risks transitioning from research to commercialization. Failure to secure adequate funding or achieve regulatory approvals could materially impact the company's viability.
Metagenomi's moat lies in its proprietary genome editing platform and intellectual property portfolio. However, as an early-stage company without approved products or commercial revenues, its competitive advantage depends on successful development and protection of its technology, regulatory approvals, and eventual market acceptance. The rapidly evolving genome editing field presents both opportunities and competitive challenges.
• Need for Additional Capital: Metagenomi requires substantial additional funding to support research, development, clinical trials, regulatory approval, manufacturing, and commercialization. Failure to raise capital on acceptable terms could delay or terminate programs.
• Early-Stage Development Risks: All programs are in early research stages with high risk of failure. The company has not initiated clinical trials or generated revenue, making future success uncertain.
• Regulatory and Commercialization Risks: Obtaining regulatory approvals and successfully commercializing product candidates involve complex, costly, and uncertain processes. Market acceptance and reimbursement are not guaranteed.
• Operational Risks: Transitioning from research to clinical development and commercialization requires significant organizational changes and resources, which may present challenges.
• Intellectual Property Risks: Maintaining and defending intellectual property rights is critical. The company may face claims of infringement or challenges to its patents.
Business trends: Continued advancement of genome editing platform and MGX-001 candidate toward clinical development amid sustained operating losses.
Execution milestones: Progression of MGX-001 IND submission, securing additional funding, and transitioning from research to clinical and commercial operations.
Key risks: Need for substantial capital, regulatory approval uncertainties, early-stage development challenges, and operational scaling risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Metagenomi, Inc. is an early-stage biotechnology company focused on genome editing technologies and product candidates.
- The company commenced operations in September 2018 and has not yet initiated clinical development of any product candidate.
- All programs are in research or lead optimization stages with high risk of failure.
- Metagenomi has not generated revenue from product sales and may never become profitable.
- The company has incurred significant operating losses since inception, with net losses of $87.9 million in 2025 and $78.1 million in 2024, and an accumulated deficit of $310.9 million as of December 31, 2025.
- Operations have been financed primarily through issuing convertible preferred units, convertible promissory notes, collaboration agreements, and IPO proceeds.
- The company expects to incur increasing operating losses as it advances research, initiates clinical trials, seeks regulatory approvals, establishes manufacturing capabilities, and commercializes products.
- Metagenomi filed a Shelf Registration Statement in March 2025 permitting sale of up to $250 million in securities and an ATM Sales Agreement for up to $75 million, though no shares were sold under the ATM as of December 31, 2025.
- The company’s ability to generate revenue depends on successful identification, development, regulatory approval, manufacturing, marketing, and market acceptance of product candidates, alone or with collaborators.
- Metagenomi faces risks including the need for substantial additional funding, potential delays or failures in product development, regulatory challenges, competition, intellectual property issues, and operational risks transitioning from research to clinical and commercial stages.
- As of September 30, 2026, the company had $36.1 million in cash and cash equivalents, current assets of $110.9 million, current liabilities of $32.3 million, a current ratio of 3.43, and a cash ratio of 1.12, indicating liquidity to support near-term operations.
- The company reported a net loss of $21.1 million and basic and diluted EPS of -$0.56 for the quarter ended September 30, 2026.
- Recent quarterly reports show continued losses and revenue shortfalls relative to expectations.
- MGX-001, a product candidate, advanced toward IND submission as of August 2026.
- The company’s operating plan and capital needs may change due to unknown factors, and additional funding may be required sooner than planned.
Generated 2026-11-11
- S1 | 2026-03-05 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-08-11 | www.nasdaq.com | Metagenomi Records Wider Q2 Loss As MGX-001 Advanced Toward IND Submission | https://www.nasdaq.com/articles/metagenomi-records-wider-q2-loss-mgx-001-advanced-toward-ind-submission
- N2 | 2026-08-10 | www.nasdaq.com | Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/metagenomi-therapeutics-mgx-reports-q2-loss-lags-revenue-estimates
- N3 | 2026-08-06 | www.nasdaq.com | Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/amphastar-pharmaceuticals-amph-q2-earnings-and-revenues-top-estimates
- N4 | 2026-08-04 | www.nasdaq.com | Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/personalis-psnl-reports-q2-loss-tops-revenue-estimates
- N5 | 2026-05-12 | www.nasdaq.com | Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/metagenomi-therapeutics-mgx-reports-q1-loss-misses-revenue-estimates
- N6 | 2026-05-07 | www.nasdaq.com | Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/assembly-biosciences-asmb-reports-q1-loss-misses-revenue-estimates
- N7 | 2026-03-05 | www.nasdaq.com | Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/metagenomi-therapeutics-mgx-reports-q4-loss-misses-revenue-estimates
- N8 | 2026-02-26 | www.nasdaq.com | Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates | https://www.nasdaq.com/articles/amphastar-pharmaceuticals-amph-q4-earnings-and-revenues-lag-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


